The Journal of Heart and Lung Transplantation
Volume 26, Issue 7 , Pages 750-752 , July 2007

Alemtuzumab (Campath 1H) as Successful Salvage Therapy for Recurrent Steroid-resistant Heart Transplant Rejection

  • Kenneth J. Woodside, MD
    • ,
  • Scott D. Lick, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Scott D. Lick, MD, Division of Cardiothoracic Surgery, Department of Surgery, University of Texas Medical Branch, 6.120 John Sealy Annex 0528, 301 University Boulevard, Galveston, TX 77555-0528. Telephone: 409-772-1203. Fax: 409-772-1421.

Received 5 January 2007 ,Revised 16 March 2007 ,Accepted 13 April 2007.

References 

  1. Magliocca JF, Knechtle SJ. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transplant Int. 2006;19:705–714
  2. Morris PJ, Russell NK. Alemtuzumab (Campath-1H): a systematic review in organ transplantation. Transplantation. 2006;81:1361–1367
  3. Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg. 2005;200:505–515
  4. Knechtle SJ, Fernandez LA, Pirsch JD, et al. Campath-1H in renal transplantation: the University of Wisconsin experience. Surgery. 2004;136:754–760
  5. Thomas PG, Woodside KJW, Lappin JA, Vaidya S, Rajaraman S, Gugliuzza KK. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Transplantation (in press).
  6. Calne RY. Prope tolerance—the future of organ transplantation from the laboratory to the clinic. Transplant Immunol. 2004;13:83–86
  7. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (Campath-1H). Transplantation. 2003;76:120–129
  8. Kirk AD, Mannon RB, Kleiner DE, et al. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation. 2005;80:1051–1059
  9. Basu A, Ramkumar M, Tan HP, et al. Reversal of acute cellular rejection after renal transplantation with Campath-1H. Transplant Proc. 2005;37:923–926
  10. Friend PJ, Rebello P, Oliveira D, et al. Successful treatment of renal allograft rejection with a humanized antilymphocyte monoclonal antibody. Transplant Proc. 1995;27:869–870
  11. Thomas PG, Ishihara K, Vaidya S, Gugliuzza KK. Campath and renal transplant rejection. Clin Transplant. 2004;18:759–761
  12. Csapo Z, Benavides-Viveros C, Podder H, Pollard V, Kahan BD. Campath-1H as rescue therapy for the treatment of acute rejection in kidney transplant patients. Transplant Proc. 2005;37:2032–2036
  13. McCurry KR, Iacono A, Zeevi A, et al. Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg. 2005;130:528–537
  14. Reams BD, Davis RD, Curl J, Palmer SM. Treatment of refractory acute rejection in a lung transplant patient with Campath 1H. Transplantation. 2002;74:903–904
  15. Lenihan DJ, Alencar AJ, Yang D, et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. Blood. 2004;104:655–658
  16. Basquiera AL, Berretta AR, Garcia JJ, Palazzo ED. Coronary ischemia related to alemtuzumab therapy. Ann Oncol. 2004;15:539–540
  17. Oshima K, Sakata-Yanagimoto M, Asano-Mori Y, et al. Cardiac complications after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab. Bone Marrow Transplant. 2005;36:821–824
  18. Lundin J, Kennedy B, Dearden C, Dyer MJS, Österborg A. No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome. Blood. 2005;105:4148–4149
  19. Knechtle SJ, Pirsch JD, Frechner JH, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant. 2003;3:722–730
  20. Roa V, Prisch JD, Becker BN, Knechtle SJ. Sirolimus monotherapy following Campath-1H induction. Transplant Proc. 2003;35(suppl 3A):128S–130S
  21. Tan JP, Kaczorowski DJ, Basu A, et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant. 2006;6:2409–2417
  22. Fishbein MC, Kobashigawa J. Biopsy-negative cardiac transplant rejection: etiology, diagnosis, and therapy. Curr Opin Cardiol. 2004;19:166–169
  23. Friend PJ, Waldmann H, Hale G, et al. Reversal of allograft rejection using the monoclonal antibody, Campath-1G. Transplant Proc. 1991;23:2253–2254

PII: S1053-2498(07)00362-2

doi: 10.1016/j.healun.2007.04.012

The Journal of Heart and Lung Transplantation
Volume 26, Issue 7 , Pages 750-752 , July 2007

Article Tools

* Image Usage & Resolution